At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 57 enrolled
Drug / intervention
BYM338 active drug +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled Multi-center Study of BYM338 for Treatment of Cachexia in Patients With Stage IV Non-small Cell Lung Cancer or Stage III/IV Adenocarcinoma of the Pancreas
In Brief
A Phase 2 clinical trial evaluating BYM338 active drug and Placebo for Cachexia. Completed, enrolled 57 participants across 10 sites in 5 countries.
Detailed Summary
A safety \& efficacy clinical study of the investigational medicinal product BYM338 for the treatment of unintentional weight loss in patients with cancer of the lung or the pancreas
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCachexia
CountriesLithuania, Romania, Switzerland, United Kingdom, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2011
First PostedSep 2011
Primary CompletionApr 2014
TodayJul 2026
First PostedSep 13, 2011
Enrollment StartAug 1, 2011
Primary CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 14.8 years ago
Interventions
BYM338 active drugdrug
Placebodrug